Advertisement

Tumor Biology

, Volume 37, Issue 2, pp 2145–2152 | Cite as

Low-level expression of microRNA-375 predicts poor prognosis in hepatocellular carcinoma

  • Na Zhou
  • Jinhua Wu
  • Xiang Wang
  • Zhao Sun
  • Qin Han
  • Lin Zhao
Original Article

Abstract

MicroRNAs are predicted to play fundamental roles in the tumorigenesis of hepatocellular carcinoma (HCC). MiR-375 is frequently downregulated in HCC and acts as a tumor suppressor by targeting multiple oncogenes. The objective of this study was to evaluate miR-375 expression and its relevance to the prognosis of HCC. MiR-375 expression was measured in cancerous tissues using qRT-PCR and dichotomized based on a median cutoff. The association between miR-375 expression and clinicopathological parameters and prognosis was subsequently determined. Expression levels of miR-375 were detected in a cohort of 38 HCC patients who underwent curative surgery. No significant correlations were observed between miR-375 expression and clinicopathological parameters, such as gender, age, performance status, preoperative serum AFP level, histological grade, HBV-DNA copy number, ascites, cirrhosis, tumor size, number of tumor nodules, and macrovascular invasion. However, miR-375 expression differs across CLIP scores significantly (p < 0.05). A trend toward poorer disease-free survival (DFS) was observed in patients with lower miR-375 expression compared to those with higher miR-375 expression (p = 0.307). Multivariate analysis demonstrated that low miR-375 expression was an independent prognostic predictor for progression (p = 0.032, risk ratio 3.273). Subgroup analysis revealed that low expression of miR-375 was significantly associated with adverse DFS in patients with poorly differentiated histology, higher serum AFP level (≥400 ng/ml), and advanced tumor stage (CLIP score 1∼3) (p = 0.017, 0.009, and 0.024, respectively). Our study demonstrates that miR-375 expression is significantly correlated with DFS and may be a potential prognostic biomarker of disease progression in HCC.

Keywords

Hepatocellular carcinoma Invasion MicroRNA-375 

Abbreviations

HCC

Hepatocellular carcinoma

HBV

Hepatitis B virus

qRT-PCR

Quantitative reverse transcription polymerase chain reaction

AFP

Alpha-fetoprotein

ECOG PS

The Eastern Cooperative Oncology Group Performance Status

CLIP

The Cancer of the Liver Italian Program

TACE

Transcatheter hepatic arterial chemoembolization

DFS

Disease-free survival

OS

Overall survival

Notes

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (No. 81101588).

Conflicts of interest

None.

Authors’ contributions

Na Zhou: conceived the study and managed its design and coordination.

Jinhua Wu and Wang Xiang: analysis and interpretation of data.

Zhao Sun and Qin Han: have given final approval of the version to be published.

Lin Zhao: have made substantial contributions to conception and design.

Supplementary material

13277_2015_3841_MOESM1_ESM.doc (28 kb)
ESM 1 (DOC 28 kb)
13277_2015_3841_MOESM2_ESM.doc (28 kb)
ESM 2 (DOC 27 kb)
13277_2015_3841_MOESM3_ESM.doc (44 kb)
ESM 3 (DOC 44 kb)
13277_2015_3841_Fig4_ESM.jpg (26 kb)
Supplementary Fig. 1

The melting curves and amplification curves of real-time PCR of miR-375. (A) melting curves; (B) amplification curve (JPEG 26 kb)

13277_2015_3841_MOESM4_ESM.tif (1.9 mb)
High Resolution Image (TIFF 1947 kb)

References

  1. 1.
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. Clin Oncol. 2006;24(14):2137–50.CrossRefGoogle Scholar
  2. 2.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.CrossRefPubMedGoogle Scholar
  3. 3.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMedGoogle Scholar
  4. 4.
    Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48 Suppl 1:S20–37.CrossRefPubMedGoogle Scholar
  5. 5.
    Llovet JM, Burroughs A, Bruix J. Hepatocellularcarcinoma. Lancet. 2003;362(9399):1907–17.CrossRefPubMedGoogle Scholar
  6. 6.
    Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30(6):1434–40.CrossRefPubMedGoogle Scholar
  7. 7.
    European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.CrossRefGoogle Scholar
  8. 8.
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.CrossRefPubMedGoogle Scholar
  9. 9.
    Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T. ShimotohnoK. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 2006;25(17):2537–45.CrossRefPubMedGoogle Scholar
  10. 10.
    Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology. 2008;47(6):1955–63.CrossRefPubMedGoogle Scholar
  11. 11.
    Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology. 2008;47(3):897–907.CrossRefPubMedGoogle Scholar
  12. 12.
    Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene. 2008;27(43):5651–61.CrossRefPubMedGoogle Scholar
  13. 13.
    Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A. 2010;107(1):264–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinomacells. Cancer Res. 2009;69(14):5761–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009;28(40):3526–36.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest. 2012;122(8):2884–97.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature. 2004;432(7014):226–30.CrossRefPubMedGoogle Scholar
  18. 18.
    Liu AM, Poon RT, Luk JM. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun. 2010;394(3):623–7.CrossRefPubMedGoogle Scholar
  19. 19.
    He XX, Chang Y, Meng FY, Wang MY, Xie QH, Tang F, et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 2012;31(28):3357–69.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhao J, Wang W, Huang Y, Wu J, Chen M, Cui P, et al. HBx elevates oncoprotein AEG-1 expression to promote cell migration by downregulating miR-375 and miR-136 in malignant hepatocytes. DNA Cell Biol. 2014;33(10):715–22.CrossRefPubMedGoogle Scholar
  21. 21.
    Yin J, Hou P, Wu Z, Wang T, Nie Y. Circulating miR-375 and miR-199a-3p as potential biomarkers for the diagnosis of hepatocellular carcinoma. Tumour Biol. 2015. [Epub ahead of print].Google Scholar
  22. 22.
    A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators.Hepatology. 1998; 28(3): 751–5.Google Scholar
  23. 23.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMedGoogle Scholar
  24. 24.
    Yan JW, Lin JS, He XX. The emerging role of miR-375 in cancer. Int J Cancer. 2014;135(5):1011–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Zhou J, Song S, He S, Zhu X, Zhang Y, Yi B, et al. MicroRNA-375 targets PDK1 in pancreatic carcinoma and suppresses cell growth through the Akt signaling pathway. Int J Mol Med. 2014;33(4):950–6.PubMedGoogle Scholar
  26. 26.
    Mathé EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res. 2009;15(19):6192–200.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Tsukamoto Y, Nakada C, Noguchi T, Tanigawa M, Nguyen LT, Uchida T, et al. MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res. 2010;70(6):2339–49.CrossRefPubMedGoogle Scholar
  28. 28.
    Harris T, Jimenez L, Kawachi N, Fan JB, Chen J, Belbin T, et al. Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas. Am J Pathol. 2012;180(3):917–28.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Chang C, Shi H, Wang C, Wang J, Geng N, Jiang X, et al. Correlation of microRNA-375 downregulation with unfavorable clinical outcome of patients with glioma. Neurosci Lett. 2012;531(2):204–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Kowalik MA, Saliba C, Pibiri M, Perra A, Ledda-Columbano GM, Sarotto I, et al. Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice. Hepatology. 2011;53(6):2086–96.CrossRefPubMedGoogle Scholar
  31. 31.
    Ho CM, Lee PH, Hu RH. Clinical correlation of miR-375 and alpha-fetoprotein in hepatocellular carcinoma: comparison in mice and humans. Hepatology. 2011;54(3):1105–6. author reply 1106.CrossRefPubMedGoogle Scholar
  32. 32.
    Ding L, Xu Y, Zhang W, Deng Y, Si M, Du Y, et al. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res. 2010;20(7):784–93.CrossRefPubMedGoogle Scholar
  33. 33.
    Kong KL, Kwong DL, Chan TH, Law SY, Chen L, Li Y, et al. MicroRNA-375 inhibits tumor growth and metastasis in esophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut. 2012;61(1):33–42.CrossRefPubMedGoogle Scholar
  34. 34.
    Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood. 2008;111(1):379–82.CrossRefPubMedGoogle Scholar
  35. 35.
    Lee SG, Su ZZ, Emdad L, Sarkar D, Franke TF, Fisher PB. Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling. Oncogene. 2008;27(8):1114–21.CrossRefPubMedGoogle Scholar
  36. 36.
    Chang Y, Yan W, He X, Zhang L, Li C, Huang H, et al. miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions. Gastroenterology. 2012;143(1):177–87.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Na Zhou
    • 1
  • Jinhua Wu
    • 2
  • Xiang Wang
    • 1
  • Zhao Sun
    • 1
  • Qin Han
    • 2
  • Lin Zhao
    • 1
  1. 1.Department of Oncology, Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingPeople’s Republic of China
  2. 2.Institute of Basic Medical Sciences Chinese Academy of Medical SciencesSchool of Basic Medicine Peking Union Medical CollegeBeijingPeople’s Republic of China

Personalised recommendations